- Home
- RILY vs HURA Comparison
RILY vs HURA Comparison
Compare RILY & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RILY | HURA |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | United States |
| Employees | 2056 | 19 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.6M | 87.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RILY | HURA |
|---|---|---|
| Price | $7.80 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 578.4K | ★ 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $0.41 |
| 52 Week High | $10.97 | $4.41 |
Technical Indicators
Market Signals| Indicator | RILY | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 69.81 |
| Support Level | $4.78 | $1.56 |
| Resistance Level | $10.97 | $1.83 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 93.01 | 94.60 |
Price Performance
Historical ComparisonAbout RILY B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.